Jpmorgan Chase & CO Gossamer Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 694 shares of GOSS stock, worth $589. This represents 0.0% of its overall portfolio holdings.
Number of Shares
694
Previous 694
-0.0%
Holding current value
$589
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding GOSS
# of Institutions
108Shares Held
167MCall Options Held
430KPut Options Held
519K-
Nea Management Company, LLC Timonium, MD18.1MShares$15.4 Million1.37% of portfolio
-
Siren, L.L.C. New York, NY13.3MShares$11.3 Million0.65% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$9.99 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY9.19MShares$7.81 Million2.2% of portfolio
-
Arch Venture Management, LLC Chicago, IL8.06MShares$6.85 Million4.79% of portfolio
About Gossamer Bio, Inc.
- Ticker GOSS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,954,000
- Market Cap $79.9M
- Description
- Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...